

BACTERIAL MENINGITIS RAPID TEST

Detection of bacterial pathogens associated with Meningitis

Bacterial meningitis, an infectious disease-causing inflammation of the meninges, has significant global morbidity and mortality. Despite early diagnosis and adequate treatment, 8-15% of patients die within 24-48 hours of symptom onset.

Prompt and proper diagnosis and treatment are crucial to prevent death and lifelong disability among survivors. The introduction and widespread use of vaccines have led to a substantial decrease in meningitis cases, reducing global deaths by 21% from 1990 to 2016.

Young children are at the highest risk, with new-borns vulnerable to Group B streptococcus and young children at higher risk from meningococcus, pneumococcus, and *Haemophilus influenzae*. Meningococcal disease is a concern for young adults and adolescents, while pneumococcal disease poses a particular risk for the elderly.

Bacterial meningitis requires immediate antibiotic treatment, and point-of-care PCR tests using cerebrospinal fluid (CSF) offer promise in accelerating diagnosis by detecting multiple species simultaneously.

Detection Method: Real-Time PCR

Result Time: Less than I hour

Sample Volume: 300µl Sample Type: CSF





VIVALYTIC

Cartridge Based Testing Platform

The Bacterial meningitis rapid test on Vivalytic offered by Bosch, a point of care platform brought to the market by Randox Laboratories. The Vivalytic system is a fully automated, cartridge-based platform capable of both High-Plex and Low-Plex patient testing. Each easy-to-use cartridge contains all necessary reagents, is a closed system to minimise risk and can be conveniently stored at room temperature.

Vivalytic Key Features:

- Cartridge based platform
- Fully-automated
- Suitable for both non-laboratory & laboratory settings
- Small footprint device
- Rapid turnaround from sample entry to results

VIVALYTIC WORKFLOW

4 Easy Steps for Optimised Workflow









To find out more email: marketing@randox.com

